Salmeterol xinafoate

ๆ˜”่˜้…ธๆฒ™็พŽ็‰น็ฝ—

Report date: 2026/03/23 20:03:44
NME

Base Information

Drug NameSalmeterol xinafoate
Drug Alias Nameๆฒ™็พŽ็‰น็ฝ—salmeterolumๆฒ™็พŽ็‰น็ฝ—็พŸ่˜็”ฒ้…ธ็›ๆฒ™็พŽ็‰น็ฝ—ๆ˜”่˜็”ฒ้…ธ็›ๆฒ™็พŽ็‰น็ฝ—ๆ˜”่˜้…ธ้…ฏ +[18]ย 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionBeta-2 adrenergic receptor agonists
TargetsBeta-2 adrenergic receptor
Therapy Area/IndicationsLocalized submental fatPulmonary Disease, Chronic ObstructiveBronchial Spasm +[5]ย 
Global Approved IndicationsPulmonary Disease, Chronic ObstructiveAsthma
Approved Indications in ChinaAsthma
Original Approved Country/TerritoryUnited States
Original Approved Date1994/02/04
Country/TerritoryUnited StatesMainland ChinaJapan
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesGlaxosmithkline Plc
China Registration ClassN/A

Develop Information

Active CompaniesGlaxosmithkline Plc
Inactive CompaniesC.H. Boehringer Sohn Ag & Co. KgNeothetics, IncTeva Branded Pharmaceutical Products R&D Inc
Active IndicationsPulmonary Disease, Chronic ObstructiveBronchial SpasmAsthma, Exercise-Induced +[4]ย 
Inactive IndicationsLocalized submental fat

Other Information

ATC CodeR03AC12
Related LinksWikipediaDrugBankKEGG